Elanco Animal Health (ELAN) Could Be 28% Undervalued As Conference Focus Turns To Growth
Elanco Animal Health (ELAN) is back in the spotlight ahead of its presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, with senior leadership set to outline the company’s current priorities.
Recent trading has been softer, with the share price down 6.5% over the past month and 6.2% over the last quarter. Even so, Elanco Animal Health still shows a 1-year total shareholder return of 16.8% and a 3-year total shareholder return close to a 2x gain, suggesting longer term momentum remains intact even as the stock cools ahead of the conference.
Scan how Elanco Animal Health compares with other veterinary and pharma players that are showing strong price and fundamentals momentum using our curated list of 16 high quality undiscovered gems.
Elanco Animal Health has put up solid long term shareholder returns even as the share price has cooled in recent weeks. The real test now is whether that business strength still comes at a reasonable price.
Most Popular Narrative: 28% Undervalued
Elanco Animal Health closed at $22.42, while the most widely followed narrative places fair value at $31.21, so the debate now is whether the current price fully reflects the pipeline, margin targets and execution risks described by analysts using a 7.24% discount rate.
Elanco anticipates an acceleration in organic constant currency revenue growth of 4% to 6%, driven by innovation and market expansion. This is expected to impact revenue growth. The successful launch of six potential blockbuster products and exceeding innovation revenue targets for 2024 positions Elanco for strong innovation contributions in 2025, anticipated to increase innovation revenue, which would influence earnings.
See why 12 investors see Elanco Animal Health as 28% undervalued.
Result: Fair Value of $31.21 (UNDERVALUED)
Still, Elanco Animal Health faces real swing factors, including foreign exchange pressure on overseas sales and the risk that new products like Zenrelia and Credelio Quattro scale more slowly than expected.
Find out about the key risks to this Elanco Animal Health narrative.
Next Steps
If the mixed sentiment on Elanco Animal Health has you on the fence, move quickly, review the data first hand, and then weigh the 4 key rewards
Looking for more investment ideas beyond Elanco Animal Health?
If Elanco Animal Health has sharpened your interest, do not stop here. Broaden your watchlist with other opportunities that match your risk profile and income goals.
- Target stronger return potential by scanning 33 high quality undervalued stocks that combine appealing prices with solid underlying businesses.
- Build a steadier income stream by reviewing 6 dividend fortresses that focus on higher yields with support from underlying fundamentals.
- Prioritize capital protection by filtering for 30 resilient stocks with low risk scores that keep risk scores tighter while still offering equity market exposure.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com